vs
Mind Medicine (MindMed) Inc.（DFTX）与OneMedNet Corp（ONMD）财务数据对比。点击上方公司名可切换其他公司
Mind Medicine (MindMed) Inc.的季度营收约是OneMedNet Corp的1.0倍（$906.0K vs $890.0K），OneMedNet Corp净利率更高（-352.8% vs -2634.0%，领先2281.2%），OneMedNet Corp同比增速更快（3323.1% vs -16.1%）
Definium Therapeutics（前称MindMed）是一家总部位于纽约的生物技术企业，专注于致幻剂及更广泛的精神可塑性药物的临床与治疗应用开发，在中枢神经药物研发领域深耕相关创新疗法的落地潜力。
OneMedNet Corp是一家总部位于美国的医疗科技企业，提供面向医学影像与患者健康信息的安全云数据共享及工作流解决方案，服务覆盖医疗机构、支付方及生命科学领域机构，核心运营市场为北美地区。
DFTX vs ONMD — 直观对比
营收规模更大
DFTX
是对方的1.0倍
$890.0K
营收增速更快
ONMD
高出3339.2%
-16.1%
净利率更高
ONMD
高出2281.2%
-2634.0%
损益表 — Q4 FY2023 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $906.0K | $890.0K |
| 净利润 | $-23.9M | $-3.1M |
| 毛利率 | — | 20.7% |
| 营业利润率 | -2450.8% | -353.4% |
| 净利率 | -2634.0% | -352.8% |
| 营收同比 | -16.1% | 3323.1% |
| 净利润同比 | -386.7% | -32.3% |
| 每股收益（稀释后） | $-0.58 | $-0.06 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DFTXONMD
| Q4 25 | — | $890.0K | ||
| Q3 25 | — | $177.0K | ||
| Q2 25 | — | $155.0K | ||
| Q1 25 | — | $137.0K | ||
| Q3 24 | — | $142.0K | ||
| Q2 24 | — | $227.0K | ||
| Q1 24 | — | $248.0K | ||
| Q4 23 | $906.0K | $322.0K |
净利润DFTXONMD
| Q4 25 | — | $-3.1M | ||
| Q3 25 | — | $-741.0K | ||
| Q2 25 | — | $3.0M | ||
| Q1 25 | — | $-1.9M | ||
| Q3 24 | — | $-2.1M | ||
| Q2 24 | — | $-3.6M | ||
| Q1 24 | — | $-2.1M | ||
| Q4 23 | $-23.9M | $-2.5M |
毛利率DFTXONMD
| Q4 25 | — | 20.7% | ||
| Q3 25 | — | -125.4% | ||
| Q2 25 | — | -155.5% | ||
| Q1 25 | — | -163.5% | ||
| Q3 24 | — | -59.2% | ||
| Q2 24 | — | -44.9% | ||
| Q1 24 | — | -27.8% | ||
| Q4 23 | — | -5.0% |
营业利润率DFTXONMD
| Q4 25 | — | -353.4% | ||
| Q3 25 | — | -1262.7% | ||
| Q2 25 | — | -1331.0% | ||
| Q1 25 | — | -1623.4% | ||
| Q3 24 | — | -1645.1% | ||
| Q2 24 | — | -1081.1% | ||
| Q1 24 | — | -847.2% | ||
| Q4 23 | -2450.8% | -585.7% |
净利率DFTXONMD
| Q4 25 | — | -352.8% | ||
| Q3 25 | — | -418.6% | ||
| Q2 25 | — | 1923.9% | ||
| Q1 25 | — | -1388.3% | ||
| Q3 24 | — | -1449.3% | ||
| Q2 24 | — | -1581.1% | ||
| Q1 24 | — | -850.4% | ||
| Q4 23 | -2634.0% | -775.2% |
每股收益（稀释后）DFTXONMD
| Q4 25 | — | $-0.06 | ||
| Q3 25 | — | $-0.01 | ||
| Q2 25 | — | $0.07 | ||
| Q1 25 | — | $-0.06 | ||
| Q3 24 | — | $-0.07 | ||
| Q2 24 | — | $-0.14 | ||
| Q1 24 | — | $-0.08 | ||
| Q4 23 | $-0.58 | $2.90 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $99.7M | $585.0K |
| 总债务越低越好 | — | $220.0K |
| 股东权益账面价值 | $78.1M | $-3.0M |
| 总资产 | $124.5M | $2.2M |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资DFTXONMD
| Q4 25 | — | $585.0K | ||
| Q3 25 | — | $149.0K | ||
| Q2 25 | — | $122.0K | ||
| Q1 25 | — | $144.0K | ||
| Q3 24 | — | $1.9M | ||
| Q2 24 | — | $407.0K | ||
| Q1 24 | — | $174.0K | ||
| Q4 23 | $99.7M | $47.0K |
总债务DFTXONMD
| Q4 25 | — | $220.0K | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | $2.3M | ||
| Q3 24 | — | $2.3M | ||
| Q2 24 | — | $2.4M | ||
| Q1 24 | — | — | ||
| Q4 23 | — | $465.0K |
股东权益DFTXONMD
| Q4 25 | — | $-3.0M | ||
| Q3 25 | — | $-3.9M | ||
| Q2 25 | — | $-3.8M | ||
| Q1 25 | — | $-16.6M | ||
| Q3 24 | — | $-14.3M | ||
| Q2 24 | — | $-19.2M | ||
| Q1 24 | — | $-15.7M | ||
| Q4 23 | $78.1M | $-13.4M |
总资产DFTXONMD
| Q4 25 | — | $2.2M | ||
| Q3 25 | — | $1.5M | ||
| Q2 25 | — | $2.3M | ||
| Q1 25 | — | $1.7M | ||
| Q3 24 | — | $4.4M | ||
| Q2 24 | — | $1.0M | ||
| Q1 24 | — | $750.0K | ||
| Q4 23 | $124.5M | $464.0K |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-20.6M | $-1.7M |
| 自由现金流经营现金流 - 资本支出 | — | $-1.7M |
| 自由现金流率自由现金流/营收 | — | -193.0% |
| 资本支出强度资本支出/营收 | — | 0.6% |
| 现金转化率经营现金流/净利润 | — | — |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流DFTXONMD
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | $-1.6M | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-1.9M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.5M | ||
| Q4 23 | $-20.6M | $-1.7M |
自由现金流DFTXONMD
| Q4 25 | — | $-1.7M | ||
| Q3 25 | — | — | ||
| Q2 25 | — | $-2.3M | ||
| Q1 25 | — | $-2.0M | ||
| Q3 24 | — | $-1.9M | ||
| Q2 24 | — | $-1.5M | ||
| Q1 24 | — | $-1.6M | ||
| Q4 23 | — | — |
自由现金流率DFTXONMD
| Q4 25 | — | -193.0% | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -1475.5% | ||
| Q1 25 | — | -1425.5% | ||
| Q3 24 | — | -1346.5% | ||
| Q2 24 | — | -663.9% | ||
| Q1 24 | — | -626.2% | ||
| Q4 23 | — | — |
资本支出强度DFTXONMD
| Q4 25 | — | 0.6% | ||
| Q3 25 | — | 0.0% | ||
| Q2 25 | — | 1.9% | ||
| Q1 25 | — | 3.6% | ||
| Q3 24 | — | 6.3% | ||
| Q2 24 | — | 0.4% | ||
| Q1 24 | — | 2.4% | ||
| Q4 23 | — | — |
现金转化率DFTXONMD
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | -0.77× | ||
| Q1 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — | ||
| Q4 23 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
